Clinical trials
Interstitial Lung Disease Due to Systemic Disease clinical trials
Below are recruiting interstitial lung disease due to systemic disease clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT07426718Recruiting
Breath test for airway inflammation in lung diseases and healthy people
This study is testing a simple breath test (Inflammacheck device) to see if it can measure airway inflammation in people with various lung conditions, including lung cancer, pneumonia, asthma, and COPD, as well as healthy volunteers. It aims to find better ways to diagnose and monitor respiratory diseases using your breath.
Portsmouth, HampshireAges 18 years+ - NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Nanjing, JiangsuAges 18–70 - NCT06332274RecruitingPhase 3
Tislelizumab for cancer patients with minimal residual disease
This trial is for people who have completed standard cancer treatments (like surgery, chemo or radiation) and have no visible cancer on scans, but may still have very small amounts of cancer DNA in their blood. The study tests whether the drug tislelizumab can help prevent the cancer from coming back.
Villejuif, Val De MarneAges 18 years+ - NCT05486650Recruiting
Study of focused radiation after PD-1 treatment helped non-lung cancer
This observational study looks at how stereotactic (high-precision) radiation works for advanced non-small cell lung cancer that is stable after PD-1 antibody treatment (sometimes with chemotherapy). It may help doctors better understand which patients benefit from this next treatment step and what side effects to expect.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05784428Recruiting
Radiation “spot treatments” for a few metastatic or worsening spots
This trial compares giving stereotactic ablative radiotherapy as one larger treatment plan versus several smaller plans for people who have only a few cancer spots (or a few spots that are worsening). It may help control metastatic disease while aiming to protect surrounding healthy organs.
Kelowna, British ColumbiaAges 18 years+ - NCT05844462RecruitingPhase 3
Tadalafil for severe lung blood-pressure problems from COPD
This study tests whether tadalafil can improve outcomes for people with severe pulmonary hypertension caused by COPD (chronic lung disease). It compares how you do with tadalafil versus standard care, focusing on breathing symptoms and how well your heart and lungs cope.
Le Kremlin-Bicêtre, FranceAges 18–85 - NCT07193641RecruitingPhase 2
Lattice radiotherapy with standard care for slow-growing lung cancer
This trial tests whether adding a special radiotherapy technique called lattice radiotherapy to your usual cancer treatment can help control NSCLC that has started to grow in a few new spots. If you have up to 5 growing tumors and at least one measures 4.5 cm or larger, this study might be an option.
Hangzhou, ZhejiangAges 18 years+ - NCT06529822RecruitingPhase 1
Personalized cancer vaccine for solid tumors with MRD
This trial tests a personalized cancer vaccine for people with certain cancers (bladder, stomach/esophagus, melanoma, or lung) who have no visible cancer after surgery but still have tiny bits of cancer DNA in their blood (called MRD). The vaccine is designed to train your immune system to attack any remaining cancer cells.
Orlando, FloridaAges 18 years+ - NCT03331380Recruiting
Low-energy MRI study for people with or without heart disease
This study tests a special MRI method that uses lower energy exposure. It aims to improve how well researchers can scan the heart and other organs while keeping the scan as safe and comfortable as possible.
Bethesda, MarylandAges 18–100
Hear when a new Interstitial Lung Disease Due to Systemic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for interstitial lung disease due to systemic disease?
- Yes. Clin2 currently lists 36 recruiting interstitial lung disease due to systemic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a interstitial lung disease due to systemic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a interstitial lung disease due to systemic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Interstitial Lung Disease Due to Systemic Disease (Disorder)
- Interstitial Lung Disease
- Non Small Cell Lung Cancer
- Fibrotic Interstitial Lung Disease
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Lung Fibrosis Interstitial
- Rheumatoid Arthritis-Associated Interstitial Lung Disease
- Systemic Lupus Erythematosus
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.